Fresenius Kabi launches Methocarbamol Injection, USP in US appeared first on PharmaNewsDaily.com.

" /> Fresenius Kabi launches Methocarbamol Injection, USP in US - Business News Today
Published On: Tue, Feb 12th, 2019

Fresenius Kabi launches Methocarbamol Injection, USP in US

German pharma company Fresenius Kabi has launched Methocarbamol Injection, USP in the US in a 100 mg per mL 10 mL vial presentation.

Methocarbamol Injection, USP is to be used as a supplement to rest, physical therapy, and other measures to ease discomfort caused by acute, painful musculoskeletal conditions. It indicated for only intravenous and intramuscular use.

– president and CEO of Fresenius Kabi USA, commenting on the US launch of Methocarbamol Injection, USP, said: “We are pleased to expand our anesthesia and analgesia portfolio with the introduction of Methocarbamol Injection, a medication that can provide relief for people with acute, painful musculoskeletal conditions.”

Methocarbamol in a 100 mg per 10 mL vial presentation is now available from Fresenius Kabi.
Methocarbamol in a 100 mg per 10 mL vial presentation is now available from Fresenius Kabi. Photo courtesy of Business Wire.

Methocarbamol Injection, USP is the latest addition to Fresenius Kabi’s portfolio of drugs for anesthesia and analgesia.

In December 2018, Fresenius Kabi launched Omegaven (fish oil triglycerides) injectable emulsion in the US. Omegaven provides calories and fatty acids to pediatric patients suffering from parenteral nutrition-associated cholestasis (PNAC).

Related posts

The post Fresenius Kabi launches Methocarbamol Injection, USP in US appeared first on PharmaNewsDaily.com.

No tags for this post.